What question did this study set out to answer?

To review the immunoregulatory mechanisms of vitamin D, its association with multiple sclerosis risk and disease activity, and the evidence supporting its use as a therapeutic supplement.

July 15, 2020British Journal of PharmacologyOpen Access

Immunoregulatory effects and therapeutic potential of vitamin D in multiple sclerosis

View Full Paper

Ask AI

Bookmark

Authors

WYWei Zhen YehNuffield Orthopaedic Centre MGMelissa GresleThe University of Melbourne VJVilija JokubaitisCincinnati Children's Hospital Medical Center

Discussion

Member takes

Overview

Review reveals links between vitamin D deficiency and disease activity in multiple sclerosis, highlighting its therapeutic potential.

Key Points

To review the immunoregulatory mechanisms of vitamin D, its association with multiple sclerosis risk and disease activity, and the evidence supporting its use as a therapeutic supplement.
Synthesized observational and epidemiological data evaluating vitamin D deficiency in central nervous system demyelinating disease.
Examined cellular and molecular pathways through which vitamin D exerts immunoregulatory actions relevant to multiple sclerosis pathology.
Evaluated findings from clinical studies and interventional supplementation trials.
Vitamin D deficiency associates with an increased susceptibility to developing multiple sclerosis as well as higher clinical disease activity.
Vitamin D demonstrates direct immunoregulatory effects that counteract the autoimmune and inflammatory processes driving central nervous system demyelination.
Clinical trials provide supportive evidence that vitamin D supplementation functions as a beneficial adjunctive therapy to reduce disease burden.

Cite This Study

Yeh et al. (2020) studied this question.

synapsesocial.com/papers/6a95bd1a471b35fa7b54fc56 https://doi.org/10.1111/bph.15201

View Full Paper

Ask AI

Bookmark

July 15, 2020British Journal of PharmacologyOpen Access

Immunoregulatory effects and therapeutic potential of vitamin D in multiple sclerosis

View Full Paper

Ask AI

Bookmark

Authors

WYWei Zhen YehNuffield Orthopaedic Centre MGMelissa GresleThe University of Melbourne VJVilija JokubaitisCincinnati Children's Hospital Medical Center

Discussion

Member takes

Overview

Review reveals links between vitamin D deficiency and disease activity in multiple sclerosis, highlighting its therapeutic potential.

Key Points

To review the immunoregulatory mechanisms of vitamin D, its association with multiple sclerosis risk and disease activity, and the evidence supporting its use as a therapeutic supplement.
Synthesized observational and epidemiological data evaluating vitamin D deficiency in central nervous system demyelinating disease.
Examined cellular and molecular pathways through which vitamin D exerts immunoregulatory actions relevant to multiple sclerosis pathology.
Evaluated findings from clinical studies and interventional supplementation trials.
Vitamin D deficiency associates with an increased susceptibility to developing multiple sclerosis as well as higher clinical disease activity.
Vitamin D demonstrates direct immunoregulatory effects that counteract the autoimmune and inflammatory processes driving central nervous system demyelination.
Clinical trials provide supportive evidence that vitamin D supplementation functions as a beneficial adjunctive therapy to reduce disease burden.

Cite This Study

Yeh et al. (2020) studied this question.

synapsesocial.com/papers/6a95bd1a471b35fa7b54fc56 https://doi.org/10.1111/bph.15201

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark